Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

Blood

Volumn 100, Issue 7, 2002, Pages 2399-2402

  Coustan Smith, Elaine ^a   Sancho, Jose ^a   Hancock, Michael L ^a   Razzouk, Bassem I ^a   Ribeiro, Raul C ^a   Rivera, Gaston K ^a   Rubnitz, Jeffrey E ^a   Sandlund, John T ^a   Pui, Ching Hon ^a   Campana, Dario ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; BLOOD SMEAR; BONE MARROW BIOPSY; CELL LINEAGE; CHILD; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0036786910     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1130     Document Type: Article

References (26)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia: current status and future perspectives. Lancet Oncol. 2001;2:597-607.
2. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995;85:1416-1434.
3. Foroni L, Harrison CJ, Hoffbrand AV, Potter MN. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol. 1999;105:7-24.
4. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409-417.
5. Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol. 1997;99:314-319.
6. van Rheé F, Marks DI, Lin F, etal. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia. 1995;9:329-335.
7. Martin H, Atta J, Bruecher J, et al. In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT. Ann Hematol. 1994;68:85-87.
8. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative realtime RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer. 1999;26:355-365.
9. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 1994;343:196-200.
10. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
11. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
12. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
13. Farahat N, Morilla A, Owusu-Ankomah K, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol. 1998;101:158-164.
14. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol. 1998;16:3774-3781.
15. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.
16. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:783-785.
17. Bradstock KF, Janossy G, Pizzolo G, et al. Subpopulations of normal and leukemic human thymocytes: an analysis with the use of monoclonal antibodies. J Natl Cancer Inst. 1980;65:33-42.
18. Greaves MF. Differentiation-linked leukemogenesis in lymphocytes. Science. 1986;234:697-704.
19. Janossy G, Bollum FJ, Bradstock KF, McMichael A, Rapson N, Greaves MF. Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. J Immunol. 1979;123:1525-1529.
20. Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97:2115-2120.
21. Coustan-Smith E, Sancho J, Behm F, et al. Prognostic significance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52-58.
22. Pui CH, Rivera GK, Hancock ML, et al. Risk-adapted treatment for ALL: findings from St. Jude Children's Research Hospital. In: BuchnerT, Hiddemann W, Wormann B, Schellong G, Ritter J, Creutzig U, eds. Acute Leukemias VI: Prognostic Factors and Treatment Strategies. Berlin, Germany: 1997:629-637.
23. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
24. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15:1-19.
25. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139-152.
26. Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 1999;13:1221-1226.